Literature DB >> 17303980

Oxaliplatin hypersensitivity: case report and successful repeat desensitization.

David A Edmondson1, B J Gruling, Angela M Urmanski, Stuart J Wong, Michael B Levy.   

Abstract

INTRODUCTION: Oxaliplatin is a third generation organoplatinum complex used as an antineoplastic agent in combination with fluorouracil and leucovorin for colorectal carcinoma. Hypersensitivity reactions are commonly observed to oxaliplatin, with an incidence of 12% to 16%. Desensitization protocols for oxaliplatin with premedication using steroids or antihistamines have been previously reported. We present a patient who underwent successful repeat desensitization without premedication. CASE
SUMMARY: A 43-year-old Asian male with metastatic rectal adenocarcinoma was started on chemotherapy with oxaliplatin and leucovorin followed by fluorouracil. Three hours after the first infusion of oxaliplatin, he developed generalized urticaria, which resolved with Benadryl. Similar symptoms developed after the second cycle. A desensitization protocol, without premedication, was developed for the third oxaliplatin cycle starting at 1:10,000 of the therapeutic dose followed by doubling doses thereafter until a cumulative goal dose of 175 mg was administered. Fluorouracil and leucovorin were then infused at the usual rates. Skin prick testing, before the procedure, using 5 mg/mL oxaliplatin was negative. Intracutaneous testing using dilutions of 1:1000, 1:100, and 1:10 were also negative. The patient was observed for 2 hours after the procedure without evidence of a hypersensitivity reaction. Two weeks later, the same protocol was successfully implemented for completion of his fourth cycle of chemotherapy and continued biweekly for a total of 11 cycles. Follow-up revealed tumor remission.
CONCLUSION: A desensitization protocol without premedication may be considered in those patients with a history of oxaliplatin hypersensitivity reactions with avoidance of the cumulative exposure to pretreatment medications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17303980     DOI: 10.1097/01.pap.0000249924.90645.5b

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  5 in total

1.  Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

Authors:  Nektaria Makrilia; Ekaterini Syrigou; Ioannis Kaklamanos; Leonidas Manolopoulos; Muhammad Wasif Saif
Journal:  Met Based Drugs       Date:  2010-09-20

2.  Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction.

Authors:  Simona Potenza; Guglielmo Nasti; Alessandro Ottaiano; Ottaiano Alessandro; Amelia Filippelli; Francesco Rossi; Annalisa Capuano
Journal:  Invest New Drugs       Date:  2009-04-08       Impact factor: 3.850

Review 3.  Hypersensitivity reactions to oxaliplatin and other antineoplastic agents.

Authors:  Ekaterini Syrigou; Kostas Syrigos; M Wasif Saif
Journal:  Curr Allergy Asthma Rep       Date:  2008-03       Impact factor: 4.806

4.  Effectiveness of oxaliplatin desensitization protocols.

Authors:  Susana Cortijo-Cascajares; Inmaculada Nacle-López; Ignacio García-Escobar; María José Aguilella-Vizcaíno; Alberto Herreros-de-Tejada; Hernán Cortés-Funes Castro; Miguel-Ángel Calleja-Hernández
Journal:  Clin Transl Oncol       Date:  2012-07-25       Impact factor: 3.405

5.  A case of oxaliplatin-induced immune-mediated thrombocytopenia.

Authors:  Seong Eun Suh; Moon Ju Jang; So Young Chong; Richard H Aster; Brian R Curtis; Doyeun Oh
Journal:  Blood Res       Date:  2014-03-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.